S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.96 (-2.14%)
GOOGL   157.74 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.67 (-3.80%)
GE   154.63 (-1.93%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)
S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.96 (-2.14%)
GOOGL   157.74 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.67 (-3.80%)
GE   154.63 (-1.93%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)
S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.96 (-2.14%)
GOOGL   157.74 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.67 (-3.80%)
GE   154.63 (-1.93%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)
S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.96 (-2.14%)
GOOGL   157.74 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.67 (-3.80%)
GE   154.63 (-1.93%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)
NASDAQ:LFMD

LifeMD (LFMD) Stock Price, News & Analysis

$9.65
-0.57 (-5.58%)
(As of 04:29 PM ET)
Today's Range
$9.22
$10.25
50-Day Range
$5.64
$11.53
52-Week Range
$1.40
$12.01
Volume
709,676 shs
Average Volume
843,226 shs
Market Capitalization
$389.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.20

LifeMD MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
7.6% Upside
$10.20 Price Target
Short Interest
Bearish
8.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.46mentions of LifeMD in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.14) to ($0.31) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.27 out of 5 stars

Medical Sector

2716th out of 2,784 stocks

Offices & Clinics Of Medical Doctors Industry

19th out of 21 stocks

LFMD stock logo

About LifeMD Stock (NASDAQ:LFMD)

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.

LFMD Stock Price History

LFMD Stock News Headlines

LifeMD Shares Come Back to Life on GLP-1 Business Growth
LifeMD Inc. NASDAQ: LFMD provides telehealth services to consumers in the United States. The medical sector company operates many telehealth brands, including men's telehealth brands RexMD and ShapiroMD, NavaMD female dermatology telehealth, Cleared Allergy Clinic, and LifeMD Primary Care.
LifeMD Shares Come Back to Life on GLP-1 Business Growth
LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024
The next Nvidia (and it’s not Microsoft or Facebook)
Imagine buying Bitcoin at $1,000. That would have been the trade of the decade... right? Well, I think there's an even bigger play to be made in the A.I. space.
Can WeightWatchers Regain its Mojo after Oprah Steps Down? (LFMD)
WW International Inc. (NASDAQ: WW) (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD).
Can WeightWatchers Regain Its Mojo after Oprah Steps Down?
WW International Inc. NASDAQ: WW (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD). The company made a praiseworthy strategic pivot in 2023, acquiring Sequence Inc. to enter into the GLP-1 clinical weight loss space, gaining the ability to prescribe medications like Novo Nordisk A/V NYSE: NVO owned Ozempic and Wegovy and Eli Lilly& Co. NYSE: LLY GLP-1 agonists like Mounjaro and Zepbound.
The next Nvidia (and it’s not Microsoft or Facebook)
Imagine buying Bitcoin at $1,000. That would have been the trade of the decade... right? Well, I think there's an even bigger play to be made in the A.I. space.
LifeMD Full Year 2023 Earnings: Beats Expectations
LifeMD Shares Jump on Strong 4Q
LifeMD Reports Fourth Quarter 2023 Results
Here's what to expect from LifeMD's earnings
Get Your Shopping List Ready: Here's How to Buy Pullbacks
LifeMD Insiders Placed Bullish Bets Worth US$1.24m
See More Headlines
Receive LFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LifeMD and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/11/2024
Today
4/12/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Offices & clinics of medical doctors
Sub-Industry
N/A
Current Symbol
NASDAQ:LFMD
Fax
N/A
Employees
207
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.20
High Stock Price Target
$13.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+5.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-20,600,000.00
Pretax Margin
-11.41%

Debt

Sales & Book Value

Annual Sales
$152.55 million
Book Value
$0.15 per share

Miscellaneous

Free Float
32,741,000
Market Cap
$389.57 million
Optionable
Optionable
Beta
1.43
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Justin SchreiberMr. Justin Schreiber (Age 41)
    Chairman & CEO
    Comp: $255k
  • Mr. Marc Benathen (Age 43)
    Chief Financial Officer
    Comp: $378.75k
  • Mr. Eric H. Yecies (Age 46)
    Chief Legal Officer, General Counsel & Secretary
    Comp: $332k
  • Mr. Brad Michael Roberts (Age 43)
    Chief Operating Officer
    Comp: $75k
  • Ms. Maria E. Stan CPA (Age 49)
    Controller & Principal Accounting Officer
  • Mr. Dennis Wijnker (Age 48)
    Chief Technology Officer
  • Mr. Shane Biffar
    Chief Compliance Officer & Deputy General Counsel
  • Ms. Jessica Friedeman (Age 40)
    Chief Marketing Officer
  • Mr. Stefan GalluppiMr. Stefan Galluppi (Age 37)
    Chief Innovation Officer
    Comp: $165k
  • Mr. Nicholas P. Alvarez (Age 42)
    Chief Acquisition Officer & Head of Customer Acquisition
    Comp: $141.11k

LFMD Stock Analysis - Frequently Asked Questions

Should I buy or sell LifeMD stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LifeMD in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LFMD shares.
View LFMD analyst ratings
or view top-rated stocks.

What is LifeMD's stock price target for 2024?

5 analysts have issued twelve-month price objectives for LifeMD's stock. Their LFMD share price targets range from $7.00 to $13.00. On average, they predict the company's stock price to reach $10.20 in the next year. This suggests a possible upside of 7.6% from the stock's current price.
View analysts price targets for LFMD
or view top-rated stocks among Wall Street analysts.

How have LFMD shares performed in 2024?

LifeMD's stock was trading at $8.29 at the beginning of 2024. Since then, LFMD stock has increased by 14.4% and is now trading at $9.48.
View the best growth stocks for 2024 here
.

Are investors shorting LifeMD?

LifeMD saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,650,000 shares, an increase of 37.3% from the March 15th total of 1,930,000 shares. Based on an average daily volume of 762,800 shares, the short-interest ratio is presently 3.5 days. Approximately 8.6% of the shares of the company are sold short.
View LifeMD's Short Interest
.

When is LifeMD's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our LFMD earnings forecast
.

How were LifeMD's earnings last quarter?

LifeMD, Inc. (NASDAQ:LFMD) released its quarterly earnings data on Monday, March, 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. The business earned $44.86 million during the quarter, compared to analysts' expectations of $40.65 million.

What ETF holds LifeMD's stock?

Invesco Dorsey Wright Healthcare Momentum ETF holds 140,399 shares of LFMD stock, representing 0.98% of its portfolio.

What guidance has LifeMD issued on next quarter's earnings?

LifeMD issued an update on its first quarter 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $42.0 million-$43.0 million, compared to the consensus revenue estimate of $42.5 million.

How do I buy shares of LifeMD?

Shares of LFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LFMD) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners